Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | BRD2 | P25440 | 1/20 | 0.58 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15120570 | 0.84 | KMT2A (0.81) | TSHRALDH1A1NPSR1KMT2ANPC1 | |
| SCHEMBL30511773 | 0.83 | ALDH1A1 (0.63) | TSHRKDM4EALDH1A1NPSR1KMT2A | |
| SCHEMBL30511774 | 0.83 | ALDH1A1 (0.63) | TSHRKDM4EALDH1A1NPSR1KMT2A | |
| SCHEMBL23847020 | 0.83 | ALDH1A1 (0.63) | TSHRKDM4EALDH1A1NPSR1KMT2A | |
| SCHEMBL15052436 | 0.83 | GAA (0.77) | TSHRKDM4ESMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL29483582 | 0.82 | NPC1 (0.70) | TSHRKDM4EALDH1A1NPSR1KMT2A | |
| SCHEMBL20387483 | 0.82 | NPC1 (0.70) | TSHRKDM4EALDH1A1NPSR1KMT2A | |
| SCHEMBL11916138 | 0.82 | ALDH1A1 (0.75) | TSHRKDM4ESMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL1149672 | 0.82 | KDM4E (0.51) | TSHRKDM4ESMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL2080681 | 0.81 | TP53 (0.65) | TSHRSMN1; SMN2ALDH1A1NPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2291377-B1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2015-02-18 | — | — | EP | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| EP-2291377-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | Avexa Limited (AU) | 2011-03-09 | — | — | EP | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| WO-2010000031-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010000031-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | TPMT, DPYD, IMPDH1 | TSHR 4240/4885KDM4E 1918/4885SMN1; SMN2 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.